title: Minimally differentiated acute myeloid leukemia in Taiwan: predominantly occurs in children less than 3 years and adults between 51 and 70 years.
abstract: Acute myeloid leukemia (AML) with minimal differentiation was usually referred to as acute undifferentiated leukemia in the past. With the help of immunophenotyping, this subtype of leukemia was shown to express myeloid antigens on the blasts and was designated AML-M0 by FAB Cooperative Study Group in 1991. Among the 423 consecutive newly diagnosed de novo AML at our institution, 12 (2.8%) were of M0 subtype. The proportion of M0 in AML was higher in children than in adults (8.2% vs 1.7%). Four other M0 patients referred from outside hospitals for immunophenotyping were also included in this study. There were two peaks in age distribution of these 16 patients: less than 3 years and between 51 and 70 years, respectively. Organomegaly was more common in patients with AML-M0 than in those with other subtypes (56.3% vs 29.2%, P = 0.025). The former patients had higher incidences of CD7 and CD34 expression on the leukemic cells than the latter ones (50% vs 16.9%, P = 0.003 and 69.2% vs 37.9%, P = 0.019, respectively). The patients with AML-M0 showed more frequent clonal chromosomal abnormalities in the leukemic cells than other AML patients (83.3% vs 53.9%, P = 0.039); the same is also true for complex cytogenetic aberrations (50% vs 11. 4%, P = 0.004). Adults with AML-M0 showed a lower complete remission (CR) rate and significantly poorer survival than those with non M0-AML. However there was no significant difference in outcome between the two groups of pediatric patients. In conclusion, AML-M0 is a unique subtype of leukemia that has distinct age distribution and shows different clinical and biological characteristics from other AML. Adult patients have poor prognosis. Whether pediatric patients had better outcome than adults needs to be clarified in further studies.
authors.affiliation: Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, ROC.
authors.forename: S Y
authors.initials: SY
authors.lastname: Huang
authors.forename: J L
authors.initials: JL
authors.lastname: Tang
authors.forename: S T
authors.initials: ST
authors.lastname: Jou
authors.forename: W
authors.initials: W
authors.lastname: Tsay
authors.forename: C H
authors.initials: CH
authors.lastname: Hu
authors.forename: D T
authors.initials: DT
authors.lastname: Lin
authors.forename: K S
authors.initials: KS
authors.lastname: Lin
authors.forename: K S
authors.initials: KS
authors.lastname: Lin
authors.forename: C H
authors.initials: CH
authors.lastname: Wang
authors.forename: Y C
authors.initials: YC
authors.lastname: Chen
authors.forename: M C
authors.initials: MC
authors.lastname: Shen
authors.forename: H F
authors.initials: HF
authors.lastname: Tien
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000368:Aged; D002454:Cell Differentiation / Q000502:physiology; D002648:Child; D002675:Child, Preschool; D020732:Cytogenetic Analysis; D005260:Female; D015321:Gene Rearrangement; D006801:Humans; D016130:Immunophenotyping; D007223:Infant; D007951:Leukemia, Myeloid / Q000235:genetics / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D013624:Taiwan; D016896:Treatment Outcome